Alocril Articles
King and Inyx enter strategic alliance
19 September 2005
King buys Aventis drug rights for $200M
6 January 2003
Allergan launches Alocril in USA
2 March 2000
R-PR opens $50 mill plant in Singapore
21 July 1999
R-P's ebastine "better than Claritin"
5 March 1999
Second-Quarter Earnings Up 29% At Rhone-Poulenc
30 July 1998
Double-Digit Pharma Sales Growth Boosts Rhone-Poulenc
29 April 1998
R-PR's Tilade Nebulizer Approved
20 November 1997
Rhone-Poulenc Rorer Expands In Singapore
19 May 1997
Strong Year-End Results From R-P Rorer
3 February 1997
R-PR Submits Two Supplementary NDAs
28 October 1996
R-PR Posts Profits Climb But Flat Turnover In First Half
5 August 1996
Rhone-Poulenc Rorer Beats 1st-Qtr Forecasts
6 May 1996
USA Lags Foreign Approvals, PhRMA Demonstrates
16 October 1995
R-PR Renews Bid For Fisons At 265 Pence
9 October 1995
Fisons: 41% Pretax Profits Growth In First-Half 1995
18 September 1995
Fisons pharmaceuticals: Rapitil
15 May 1995
Sweden's Astra Buys Most Of Fisons R&D Ops
27 March 1995
Fisons' CEO Says Will Focus On Pharmaceuticals
13 March 1995
Work Cut Out For New Team At Fisons
23 January 1995
Fisons/R-PR US Joint Venture Dropped
2 January 1995
Fisons Outlook Gloomy As Interims Disappoint
19 September 1994
UK INDUSTRY REPORT ON "BRIBERY" CHARGES
21 March 1994
LIKELY IMPACT ON DRUG FIRMS OF ITALIAN REFORMS
17 January 1994
EUROPEAN STOCK COMMENT
13 December 1993
FISONS "PAYS DOCTORS" TO PRESCRIBE ASTHMA DRUGS
15 November 1993
FISONS OPENS SINGAPORE PLANT
8 November 1993
"ENCOURAGING SIGNS OF RECOVERY" AT FISONS?
13 September 1993
FISONS QUIET ON TILADE PROGRESS
16 August 1993
PULMICORT TILADE TRIAL
26 July 1993
EUROPEAN STOCK COMMENT
5 July 1993
EUROPEAN STOCK COMMENT
28 June 1993
FISONS' "LAST HOPE" TILADE LAUNCHED IN USA
21 June 1993
MERGER CALL REJECTED BY FISONS
31 May 1993
FISONS DISCONTINUES TIPREDANE DEV'T
12 April 1993
FISONS FUTURE STRATEGY DIRECTION
22 February 1993
FISONS AND ALLERGAN LINK-UP
8 February 1993
FDA APPROVES 26 NEWDRUGS IN 1992
25 January 1993
FISONS STARTS SLOW RECOVERY?
18 January 1993
FDA YEAR-END DRUG APPROVALS ROLL-OUT
4 January 1993
UK FIRMS BOOSTED BY YEAR-END US APPROVALS
4 January 1993
ROCHE BUYS FISONS' UK CONSUMER HEALTH
21 December 1992
CLINTON EFFECT ON UK PHARMA COS
9 November 1992
RPSGB CANDIDATES FOR POM-TO-P SWITCHING
2 November 1992
FISONS PROFIT WARNING LEADS TO SHARE PLUNGE
22 June 1992
NEDOCROMIL IN GERMANY
25 May 1992
FISONS DIVESTS TO FOCUS ON PHARMACEUTICALS
11 May 1992
EUROPEAN ASTHMA TREATMENT MARKET
6 April 1992
EUROPEAN ASTHMA TREATMENT MARKET
6 April 1992
CHANGING FACE OF THE ASTHMA MARKET
9 March 1992
FISONS' US DIFFICULTIES BRING PROFIT DOWN 17%
9 March 1992
NO END TO FISONS' PROBLEMS?
27 January 1992
FISONS UPDATES ON LEAD R&D PRODUCTS
27 January 1992
Showing 1-54 of 54 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
